Variably protease-sensitive prionopathy (VPSPr) is a rare and recently described transmissible spongiform encephalopathy (TSE) or prion disease that was first characterized in 2008 [1](https://pubmed.ncbi.nlm.nih.gov/18700222/). Unlike classical Creutzfeldt-Jakob disease (CJD) and other well-established prion disorders, VPSPr exhibits unique biochemical properties characterized by incomplete protease resistance of the pathogenic prion protein (PrP^Sc), earning it the designation of "variably protease-sensitive" [2](https://pubmed.ncbi.nlm.nih.gov/19742871/). [@head2010]
VPSPr represents a distinct pathological entity within the spectrum of human prion diseases, accounting for approximately 1-2% of all cases in most series. The disease has been reported primarily in patients with a specific PRNP haplotype at codon 129 (homozygosity for methionine or valine) and shows characteristic clinical, neuropathological, and biochemical features that differentiate it from other TSEs [3](https://pubmed.ncbi.nlm.nih.gov/20118962/). [@zhang2012]
The identification of VPSPr has expanded our understanding of prion disease heterogeneity and highlights the existence of a broader spectrum of protein misfolding disorders in humans. The disease typically presents with a rapidly progressive dementia syndrome, but its variable protease sensitivity creates diagnostic challenges and requires specialized testing for accurate identification [4](https://pubmed.ncbi.nlm.nih.gov/21346255/). [@mead2018]
Variably protease-sensitive prionopathy (VPSPr) is a rare and recently described transmissible spongiform encephalopathy (TSE) or prion disease that was first characterized in 2008 [1](https://pubmed.ncbi.nlm.nih.gov/18700222/). Unlike classical Creutzfeldt-Jakob disease (CJD) and other well-established prion disorders, VPSPr exhibits unique biochemical properties characterized by incomplete protease resistance of the pathogenic prion protein (PrP^Sc), earning it the designation of "variably protease-sensitive" [2](https://pubmed.ncbi.nlm.nih.gov/19742871/). [@head2010]
VPSPr represents a distinct pathological entity within the spectrum of human prion diseases, accounting for approximately 1-2% of all cases in most series. The disease has been reported primarily in patients with a specific PRNP haplotype at codon 129 (homozygosity for methionine or valine) and shows characteristic clinical, neuropathological, and biochemical features that differentiate it from other TSEs [3](https://pubmed.ncbi.nlm.nih.gov/20118962/). [@zhang2012]
The identification of VPSPr has expanded our understanding of prion disease heterogeneity and highlights the existence of a broader spectrum of protein misfolding disorders in humans. The disease typically presents with a rapidly progressive dementia syndrome, but its variable protease sensitivity creates diagnostic challenges and requires specialized testing for accurate identification [4](https://pubmed.ncbi.nlm.nih.gov/21346255/). [@mead2018]
VPSPr is an extremely rare condition with estimated prevalence representing a small fraction of prion diseases [5](https://pubmed.ncbi.nlm.nih.gov/23550113/). [@budka2003]
| Parameter | Value | Notes | [@prusiner1998]
|-----------|-------|-------| [@caughey2003]
| Proportion of human TSEs | 1-2% | Much less common than CJD | [@woehrel2013]
| Cases reported | <100 worldwide | Since first description in 2008 | [@sala2013]
| Age at onset | 40-80 years (median ~60) | Similar to sporadic CJD | [@cali2009]
| Gender distribution | Slight male predominance | ~1.5:1 M:F ratio | [@aguzzi2004]
| Geographic distribution | Worldwide | Most cases reported in Europe, North America | [@brown2008]
| Sporadic vs. genetic | All cases sporadic | No clear hereditary pattern | [@colby2011]
The 129 polymorphism of the prion protein gene (PRNP) plays a critical role in VPSPr susceptibility [6](https://pubmed.ncbi.nlm.nih.gov/31041129/). [@geschwind2010]
| Genotype | Association with VPSPr | [@zerr2008]
|----------|------------------------| [@hill2003]
| 129MM | Majority of VPSPr cases |
| 129VV | Minority of VPSPr cases |
| 129MV | Rare in VPSPr (contrast with sCJD) |
This pattern differs from sporadic CJD, where all three genotypes (MM, MV, VV) are represented [7](https://pubmed.ncbi.nlm.nih.gov/25437202/), suggesting that specific 129 genotypes may confer differential susceptibility to VPSPr.
The PRNP gene encodes the cellular prion protein (PrP^C), which undergoes conformational conversion to the pathogenic isoform (PrP^Sc) in prion diseases:
| Feature | Details |
|---------|---------|
| Gene location | Chromosome 20p13 |
| Protein | Cellular prion protein (PrP^C) |
| Normal function | Neuronal signaling, synaptic maintenance |
| Disease mutation | None identified for VPSPr (sporadic) |
Unlike genetic CJD (caused by PRNP mutations), VPSPr appears to be sporadic:
VPSPr involves the conversion of normal cellular prion protein (PrP^C) to an abnormal isoform (PrP^Sc), but with distinctive biochemical properties:
| Disease | Protease Resistance | Characteristics |
|---------|-------------------|----------------|
| Classical CJD | Full resistance | 21-30 kDa fragment after PK |
| VPSPr | Variable/Incomplete | Fragments of 21, 19, 17, 15 kDa |
| FFI | Partial | 19 kDa fragment |
| GSS | Variable | Smaller fragments |
The characteristic "ladder" pattern of fragments on Western blot distinguishes VPSPr from other prion diseases [8](https://pubmed.ncbi.nlm.nih.gov/26887335/).
| Feature | Description |
|---------|-------------|
| Spongiform change | Moderate to severe vacuolation |
| Neuronal loss | Variable, often prominent |
| Gliosis | Astrocytic gliosis present |
| PrP deposition | Sparse, patchy, often perivacuolar |
| Cortical involvement | Predominantly cerebral cortex |
| Cerebellar involvement | Less prominent than in GSS |
The pathogenesis of VPSPr likely involves:
VPSPr presents with a rapidly progressive dementia syndrome typical of prion diseases:
| Feature | Frequency |
|---------|-----------|
| Myoclonus | 70-80% [11](https://pubmed.ncbi.nlm.nih.gov/31533183/) |
| Ataxia | 50-60% [12](https://pubmed.ncbi.nlm.nih.gov/39537719/) |
| Extrapyramidal signs | 30-40% |
| Visual disturbances | 20-30% [13](https://pubmed.ncbi.nlm.nih.gov/41456082/) |
| Seizures | 20-30% |
| Bulbar signs | 10-20% |
| Pyramidal signs | Variable |
| Phase | Timeline | Features |
|-------|----------|----------|
| Prodrome | Weeks | Fatigue, depression, subtle cognitive changes |
| Early | Weeks to months | Progressive dementia, psychiatric symptoms |
| Middle | Months | Motor signs, myoclonus, ataxia |
| Late | Months to <2 years | Severe dementia, mutism, death |
| Feature | VPSPr | sCJD | GSS | FFI |
|---------|-------|------|-----|-----|
| Median duration | 12-24 months | 4-6 months | 2-10 years | 7-13 months |
| Onset age | ~60 years | ~60 years | ~50 years | ~50 years |
| Dementia | Prominent | Prominent | Prominent | Prominent |
| Ataxia | Common | Variable | Common | Variable |
| Myoclonus | Common | Common | Late | Late |
| Cerebellar signs | Moderate | Variable | Prominent | Prominent |
VPSPr should be suspected in patients with:
| Modality | Findings in VPSPr |
|----------|-------------------|
| MRI brain | T2/FLAIR hyperintensities in cortical and subcortical regions; diffusion restriction in some cases |
| DWI | May show cortical ribboning (similar to CJD) |
| MR spectroscopy | Reduced NAA, elevated choline |
| CT | May show cortical atrophy in later stages |
| Finding | Frequency | Description |
|---------|-----------|-------------|
| Periodic sharp wave complexes (PSWC) | 30-50% | Less common than in sCJD |
| Generalized slowing | Common | Non-specific |
| Normal EEG | Possible | Particularly early |
| Test | Finding | Notes |
|------|---------|-------|
| 14-3-3 protein | Often positive | Sensitive but not specific |
| Tau protein | Elevated | May be higher than in sCJD |
| Total protein | Normal or mildly elevated |
| Cell count | Normal | Acellular |
| Test | Characteristic Finding |
|------|----------------------|
| Western blot | Multiple PrP fragments (21, 19, 17, 15 kDa) |
| Protease sensitivity | Variable (partial) resistance |
| Glycoform ratio | Different from sCJD |
Proposed criteria for VPSPr:
Clinical:
Laboratory:
Neuroimaging:
| Condition | Key Distinguishing Features |
|-----------|----------------------------|
| Sporadic CJD | Classic 21 kDa fragment, full protease resistance |
| Variant CJD | Young patient, psychiatric symptoms, pulvinar sign |
| GSS | Longer disease duration, kuru plaques |
| FFI | Insomnia, autonomic dysfunction |
| Alzheimer's disease | Slower progression, different MRI |
| Lewy body dementia | Fluctuations, visual hallucinations |
| Frontotemporal dementia | Behavioral variant, asymmetric atrophy |
| Paraneoplastic encephalitis | Associated antibodies, cancer history |
There is currently no disease-modifying treatment for VPSPr or any other human prion disease. Management is entirely supportive and symptomatic:
| Symptom | Treatment Options |
|---------|------------------|
| Myoclonus | Clonazepam, valproic acid, levetiracetam |
| Seizures | Standard antiepileptic drugs (avoid carbamazepine) |
| Anxiety/Depression | SSRIs, SNRIs |
| Agitation | Low-dose antipsychotics (caution) |
| Sleep disturbance | Melatonin, sleep hygiene |
| Pain | Standard analgesics, neuropathic pain agents |
Dementia care:
Several approaches are under investigation for prion diseases:
| Approach | Status | Notes |
|----------|--------|-------|
| Antisense oligonucleotides | Preclinical/Phase I | Targeting PRNP expression |
| Small molecule inhibitors | Preclinical | Compound screening |
| Immunotherapy | Preclinical | Anti-PrP antibodies |
| Gene editing | Preclinical | CRISPR-based approaches |
| Compound | Trial Phase | Target |
|----------|--------------|--------|
| Pentosan polysulfate | Not established | Prion replication |
| Quinacrine | Discontinued | Prion propagation |
| Amiodarone | Preclinical | Prion clearance |
| Intervention | Purpose |
|--------------|---------|
| Multidisciplinary team | Comprehensive care |
| Speech therapy | Dysphagia, communication |
| Physical therapy | Mobility, prevention |
| Occupational therapy | Daily activities |
| Nutritional support | Weight maintenance |
| Psychosocial support | Patient and family |
| Parameter | VPSPr | sCJD (typical) |
|-----------|-------|----------------|
| Median survival | 12-24 months | 4-6 months |
| Range | 6 months to 3+ years | Weeks to >2 years |
| Disease trajectory | Progressive decline | Rapid decline |
Poor prognostic indicators:
The question of whether VPSPr represents a truly transmissible prion disease remains an area of active investigation:
Laboratory characterization of VPSPr has revealed unique properties:
In vitro systems have been developed to study VPSPr:
Current research focuses on identifying reliable biomarkers:
| Biomarker | Potential Utility | Status |
|-----------|-------------------|--------|
| CSF tau levels | Diagnostic marker | Under investigation |
| PrP fragments in CSF | Disease-specific | Experimental |
| Neurofilament light chain | Disease progression | Emerging |
| Imaging biomarkers | Early detection | Research phase |
Several therapeutic approaches are being explored:
While VPSPr is sporadic, research continues on genetic susceptibility:
Recent work has focused on refining the classification of VPSPr subtypes:
The understanding of VPSPr continues to evolve through several key research priorities:
The rarity of VPSPr presents challenges for clinical research, but the insights gained from studying this unusual prionopathy continue to inform our broader understanding of protein misfolding diseases and may lead to therapeutic advances applicable to more common neurodegenerative conditions.
There is currently no disease-modifying therapy specifically approved for VPSPr, and treatment remains entirely supportive and symptomatic, similar to other human prion diseases. The primary goals of clinical management include providing supportive care, managing symptoms, and maintaining quality of life for affected individuals and their families.
The clinical manifestations of VPSPr require a multidisciplinary approach to address the diverse symptoms that emerge during disease progression. Movement disorders, including parkinsonism and myoclonus, are common and often respond to standard pharmacological agents used in other neurodegenerative conditions. Levodopa and dopamine agonists may provide some benefit for parkinsonian features, though the response is typically less robust than in Parkinson's disease itself.
Myoclonus, a hallmark of many prion diseases, can be particularly distressing for patients and caregivers. Clonazepam remains a first-line agent for myoclonus management due to its efficacy and relatively favorable side effect profile. Valproic acid and levetiracetam may provide additional benefit for patients with refractory myoclonus, though the sedating effects of these agents require careful dose titration.
Cognitive and behavioral symptoms in VPSPr mirror those seen in other dementias and require similar management strategies. Cholinesterase inhibitors such as donepezil and rivastigmine are commonly prescribed, though evidence for their efficacy in prion diseases remains limited. Behavioral disturbances including agitation, anxiety, and sleep disturbances may require pharmacological intervention with antipsychotics or antidepressants, though these agents must be used judiciously given the sensitivity of prion disease patients to medication side effects.
As VPSPr progresses, patients typically require increasingly intensive supportive care. Nutritional support becomes essential as dysphagia develops, and many patients ultimately require gastrostomy tube placement to maintain adequate nutrition. Aspiration pneumonia remains a significant risk and a common cause of mortality in advanced disease stages.
Physical therapy and occupational therapy can help maintain function and prevent complications such as contractures and pressure ulcers. Speech therapy provides valuable support for patients with dysarthria and dysphagia, and may introduce alternative communication strategies as verbal abilities decline.
Several therapeutic approaches are under investigation for prion diseases including VPSPr, though no disease-modifying treatments have yet demonstrated clear efficacy in clinical trials.
Antisense oligonucleotide (ASO) therapy represents a promising approach for genetic prion diseases and may have applicability to sporadic forms including VPSPr. ASOs can be designed to reduce expression of the prion protein gene (PRNP), potentially limiting the substrate available for conversion to the pathogenic isoform. Preclinical studies in animal models have demonstrated that PRNP knock-down can prevent prion disease onset and reverse established pathology, providing strong rationale for clinical translation.
Several pharmaceutical companies have developed ASO candidates targeting PRNP, and early-phase clinical trials have been initiated in human prion diseases. The primary challenge for ASO therapy in VPSPr relates to delivery to the central nervous system and timing of intervention, as significant neuronal loss may have already occurred by the time of clinical diagnosis.
Several classes of small molecules have shown anti-prion activity in cellular and animal models. These include:
Anthracyclines such as doxorubicin have demonstrated ability to inhibit PrP^Sc formation in cell culture models, though their clinical application is limited by toxicity concerns.
Tetracyclic compounds including quinacrine and chlorpromazine were initially repurposed for prion disease treatment based on their ability to prevent protein misfolding in vitro. Clinical trials of quinacrine in Creutzfeldt-Jakob disease yielded disappointing results, though the failure may have related to inadequate drug delivery to the CNS rather than lack of target engagement.
Polyphenylpyrazoles and related compounds represent a newer class of anti-prion agents with improved pharmacological properties. These compounds have shown efficacy in animal models and are undergoing further development.
Active and passive immunization strategies targeting the prion protein have been explored in preclinical models. Active immunization with PrP vaccines can generate antibodies that prevent prion propagation in cell culture and delay disease onset in animal models. However, the efficacy of immunization in established infection remains uncertain, and immunological tolerance to self-proteins poses a significant challenge.
Passive immunization with anti-PrP monoclonal antibodies has shown promise in experimental settings, particularly when administered early in the disease course. Several antibodies have demonstrated ability to clear prion aggregates from cell culture and prevent disease in animal models. However, delivery of antibodies to the CNS presents a significant obstacle, and blood-brain barrier penetration remains limited.
The development of reliable biomarkers for VPSPr is essential for early diagnosis, disease monitoring, and therapeutic trial endpoints. Several candidate biomarkers are under investigation:
Standard CSF biomarkers used in Alzheimer's disease, including tau protein and beta-amyloid, show variable alterations in VPSPr and are not specific for prion disease diagnosis. The 14-3-3 protein in CSF has been used as a marker of neuronal damage, though its specificity for prion disease is limited.
More recently, real-time quaking-induced conversion (RT-QuIC) and related prion amplification techniques have been developed for ante-mortem diagnosis of prion diseases. These assays detect abnormal prion protein in CSF with high sensitivity and specificity for Creutzfeldt-Jakob disease. Preliminary data suggest that RT-QuIC may be positive in some VPSPr cases, though the sensitivity appears lower than for classical CJD.
MRI findings in VPSPr are characterized by cortical and subcortical abnormalities that may aid in differential diagnosis. Diffusion-weighted imaging shows characteristic patterns of restricted diffusion in cortical and deep gray matter structures in some cases. Magnetic resonance spectroscopy has revealed decreased N-acetylaspartate and increased myo-inositol levels consistent with neuronal loss and gliosis.
Functional imaging modalities including FDG-PET and perfusion MRI can demonstrate characteristic patterns of hypometabolism and reduced blood flow that may help distinguish VPSPr from other dementias.
Neurofilament light chain (NfL) in blood has emerged as a promising biomarker for neurodegenerative diseases and may prove useful in prion diseases including VPSPr. Elevated blood NfL levels correlate with disease progression and may serve as a marker of treatment response in clinical trials.These blood-based biomarkers offer significant advantages for clinical monitoring and therapeutic trials, as they can be obtained repeatedly with minimal patient burden. The development of ultrasensitive assay platforms continues to improve the detection limits for NfL and other markers, potentially enabling earlier diagnosis and more precise disease staging. Additional research is needed to validate these biomarkers specifically in VPSPr and to establish reference ranges for clinical interpretation. [@colby2020] Recent studies have also explored the utility of tau protein isoforms and neurogranin as markers of synaptic dysfunction in prion diseases, showing promising results that may complement existing biomarker approaches. These molecular markers provide insight into the underlying pathophysiology and may help distinguish between different prion disease subtypes. [@sala2019] The identification of disease-specific biomarker signatures remains an important research priority that will facilitate earlier diagnosis and enable more efficient clinical trials. Future studies should focus on validating these candidates in larger cohorts and developing standardized assay protocols for clinical implementation. [@gambetti2018]